JHL Biotech’s Trastuzumab Biosimilar (JHL1188) Receives CHMP Positive Scientific Advice to Treat Breast Cancer

 JHL Biotech’s Trastuzumab Biosimilar (JHL1188) Receives CHMP Positive Scientific Advice to Treat Breast Cancer

JHL Biotech’s Trastuzumab Biosimilar (JHL1188) Receives CHMP Positive Scientific Advice to Treat Breast Cancer

Shots:
  • JHL1188 gets CHMP approval for its global Phase III clinical trial in metastatic breast cancer
  •  JHL1188 is a proposed biosimilar to trastuzumab, which is marketed by Roche under the trade name Herceptin
  •  JHL is developing 7 biosimilar including JHL1188, which is for metastatic breast cancer

Click here to read full press release/ article | Ref: Prnewswire | Image:  BioSpectrum Asia

Vartika Singh

Vartika Singh is a content writer who loves to write research articles and reports at PharmaShots. She has in-depth knowledge of the life sciences industry including the Pharma and Biotech sectors. Any articles written by her can be contacted at connect@pharmashots.com.

Related post